CTRI/2024/07/071087
Not yet recruiting
Phase 4
A Comparitive study of Dapagliflozin Vs Pioglitazone in Patients of Non Alcoholic Fatty liver disease with Type 2 Diabetes Mellitus - NI
Babra0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: E116- Type 2 diabetes mellitus with other specified complications
- Sponsor
- Babra
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1 NAFLD Fibrosis Score(Stage 1 to Stage 3\)
- •2 USG (Grade 2 \& Grade 3 fatty liver)
- •3 HbA1C 6\.5% \& above
- •4 BMI 23 kg/m² \& above
- •5 Type 2 diabetes mellitus patient on treatment of metformin (upto 2g/day)
Exclusion Criteria
- •1 Patient with heart failure, kidney failure, malignancy
- •2 Pregnant \& Lactating mothers
- •3 Habitual drinkers
- •4 Contraindication to dapagliflozin and pioglitazone
- •5 Use of steroid \&/ or other immunosuppressor
- •6 H/o mental illness or inability to co operate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trialtype 2 diabetes mellitus, NAFLD, NASHJPRN-UMIN000030548Saitama Medical University Hospital100
Recruiting
Phase 3
Effects of Dapagliflozin and Empagliflozin in Myocardial DysfunctioIRCT20111206008307N45Tabriz University of Medical Sciences75
Recruiting
Phase 3
Safety and efficacy of Dapagliflozin and sitagliptin in elderly uncontrolled type 2 diabetes mellitus patientsHealth Condition 1: E112- Type 2 diabetes mellitus with kidney complicationsCTRI/2023/06/053833Dr Mukku Venkata Pratap Reddy
Completed
Not Applicable
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)Type 2 Diabetes MellitusJPRN-UMIN000028014the Japan Society for Patient Reported Outcome (PRO)340
Completed
Not Applicable
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (sub study)Type 2 Diabetes MellitusJPRN-UMIN000029640the Japan Society for Patient Reported Outcome (PRO)40